Antion Biosciences

Antion Biosciences is a private, early-stage biotech firm operating in the high-growth sectors of RNA and cell & gene therapy from its base in Geneva, Switzerland. Founded in 2018, the company appears to be in a foundational or stealth development phase, as evidenced by its placeholder website. While specific details on its technology, pipeline, and team are not publicly disclosed, its chosen therapeutic domains suggest an ambition to tackle complex diseases through genetic modulation and cellular engineering. The company is likely pre-revenue and in a pre-clinical research stage, seeking to establish its proprietary platform and initial proof-of-concept data.

Antion Biosciences would compete in the densely populated and rapidly evolving fields of RNA and cell & gene therapy, facing competition from large biopharma companies (e.g., Roche, Novartis, Pfizer), established biotechs (e.g., Moderna, BioNTech, CRISPR Therapeutics), and dozens of well-funded private startups. Differentiation will require a truly novel technological approach or a unique application to an underserved disease area.